Effect of advanced glycation end products on platelet activation and aggregation: a comparative study of the role of glyoxal and methylglyoxal

References

• Palomo GI, Icaza NG, Mujica EV, Nunez FL, Leiva ME, Vasquez RM, Alarcon LM, Moyano DE. Prevalence of cardiovascular risk factors in adult from Talca, Chile. Rev Med Chil 2007;135(7):904–912. doi:10.4067/s0034-98872007000700011.
   PubMed Web of Science ®Google Scholar
• Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002;1(4):273–288. doi:10.1016/s1474-5151(02)00038-5.
   PubMedGoogle Scholar
• Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997;78(1):611–616. doi:10.1055/s-0038-1657598.
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Nikolaidou B, Gavriilaki E, Lazaridis A, Yiannaki E, Anyfanti P, Zografou I, Markala D, Douma S. Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diab Vasc Dis Res 2019;16(5):458–465. doi:10.1177/1479164119844691.
   PubMed Web of Science ®Google Scholar
• Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diab Res Clin Pract 2005;67(1):3–21. doi:10.1016/j.diabres.2004.09.004.
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107(9):1058–1070. doi:10.1161/CIRCRESAHA.110.223545.
   PubMed Web of Science ®Google Scholar
• Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 2013;10(3):239–245. doi:10.1177/1479164112460253.
   PubMed Web of Science ®Google Scholar
• Tsakiri EN, Iliaki KK, Hohn A, Grimm S, Papassideri IS, Grune T, Trougakos IP. Diet-derived advanced glycation end products or lipofuscin disrupts proteostasis and reduces life span in Drosophila melanogaster. Free Rad Biol Med 2013;65:1155–1163. doi:10.1016/j.freeradbiomed.2013.08.186.
   PubMed Web of Science ®Google Scholar
• Kosmopoulos M, Drekolias D, Zavras PD, Piperi C, Papavassiliou AG. Impact of advanced glycation end products (AGEs) signaling in coronary artery disease. Biochim Biophys Acta Mol Basis Dis 2019;1865(3):611–619. doi:10.1016/j.bbadis.2019.01.006.
   PubMed Web of Science ®Google Scholar
• Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 2006;21(6):1611–1617. doi:10.1093/ndt/gfl053.
   PubMed Web of Science ®Google Scholar
• Heltianu C, Manea S-A, Guja C, Mihai C, Ionescu-Tirgoviste C. Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients. Cent Eur J Biol 2008;3:243–249. doi:10.2478/s11535-008-0019-4.
   Google Scholar
• Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71(6):26B–31B. doi:10.1016/0002-9149(93)90142-y.
   PubMed Web of Science ®Google Scholar
• Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Rad Biol Med 2000;28(12):1708–1716. doi:10.1016/s0891-5849(00)00228-8.
   PubMed Web of Science ®Google Scholar
• Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147(3):654–667. PMID:7545874.
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123(7):798–813. doi:10.1161/CIRCULATIONAHA.109.913376.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb Res 2002;107(6):319–323. doi:10.1016/s0049-3848(02)00348-1.
   PubMed Web of Science ®Google Scholar
• Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diab Res Clin Pract 2000;50(1):1–16. doi:10.1016/s0168-8227(00)00160-1.
   PubMed Web of Science ®Google Scholar
• Palomo I, Moore-Carrasco R, Alarcon M, Rojas A, Espana F, Andres V, Gonzalez-Navarro H. Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci (Schol Ed) 2010;2:194–208. doi:10.2741/57.
   PubMedGoogle Scholar
• Hangaishi M, Taguchi J, Miyata T, Ikari Y, Togo M, Hashimoto Y, Watanabe T, Kimura S, Kurokawa K, Ohno M. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998;248(2):285–292. doi:10.1006/bbrc.1998.8945.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu Y, Cui B, Mi Q, Huang Y, Fan L, Chen Q, Tang J, Ferro A, Ji Y. 17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. Clin Exp Pharmacol Physiol 2007;34(10):972–978. doi:10.1111/j.1440-1681.2007.04680.x.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu Y, Mi Q, Xie L, Huang Y, Jiang Q, Chen Q, Ferro A, Liu N, Ji Y. Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced glycation end products in vitro. Int J Vitam Nutr Res 2010;80(3):168–177. doi:10.1024/0300-9831/a000019.
   PubMed Web of Science ®Google Scholar
• Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000;86(3):E50–54. doi:10.1161/01.res.86.3.e50.
   PubMed Web of Science ®Google Scholar
• Rojas A, Gonzalez D, Figueroa H, Morales MA, Romero J. Modulation of nitric oxide pathway by multiligands/RAGE axis: A crossing point on the road to microvascular complication in diabetes. Curr Enzym Inhibit 2010;6(1):34–45. doi:10.2174/157340810790712050.
   Google Scholar
• Rojas A, Mercadal E, Figueroa H, Morales MA. Advanced Glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol 2008;6(1):44–51. doi:10.2174/157016108783331312.
   PubMed Web of Science ®Google Scholar
• El Khoury J, Thomas CA, Loike JD, Hickman SE, Cao L, Silverstein SC. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994;269(14):10197–10200. PMID:8144597.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1(6):634–646. doi:10.1007/BF03401604.
   PubMed Web of Science ®Google Scholar
• Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 1996;93(20):11047–11052. doi:10.1073/pnas.93.20.11047.
   PubMed Web of Science ®Google Scholar
• Ohgami N, Nagai R, Ikemoto M, Arai H, Miyazaki A, Hakamata H, Horiuchi S, Nakayama H. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 2002;16(1):56–59. doi:10.1016/s1056-8727(01)00208-2.
   PubMed Web of Science ®Google Scholar
• Wolfs JL, Comfurius P, Rasmussen JT, Keuren JF, Lindhout T, Zwaal RF, Bevers EM. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005;62(13):1514–1525. doi:10.1007/s00018-005-5099-y.
   PubMed Web of Science ®Google Scholar
• Wahid ST, Marshall SM, Thomas TH. Increased platelet and erythrocyte external cell membrane phosphatidylserine in type 1 diabetes and microalbuminuria. Diabetes Care 2001;24(11):2001–2003. doi:10.2337/diacare.24.11.2001-a.
   PubMed Web of Science ®Google Scholar
• Wang Y, Beck W, Deppisch R, Marshall SM, Hoenich NA, Thompson MG. Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors. Am J Physiol Cell Physiol 2007;293:C328–336. doi:10.1152/ajpcell.00560.2006.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Li W, Febbraio M, Espinola RG, McCrae KR, Cockrell E, Silverstein RL. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008;118(5):1934–1943. doi:10.1172/JCI34904.
   PubMed Web of Science ®Google Scholar
• Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007;13(9):1086–1095. doi:10.1038/nm1626.
   PubMed Web of Science ®Google Scholar
• Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2001;947(1):350–355. doi:10.1111/j.1749-6632.2001.tb03961.x.
   PubMed Web of Science ®Google Scholar
• Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012;119(25):6136–6144. doi:10.1182/blood-2011-10-387506.
   PubMed Web of Science ®Google Scholar
• Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001;276(5):3195–3202. doi:10.1074/jbc.M006545200.
   PubMed Web of Science ®Google Scholar
• Ávila F, Ravello N, Zanocco AL, Gamon LF, Davies MJ, Silva E. 3-Hydroxykynurenine bound to eye lens proteins induces oxidative modifications in crystalline proteins through a type I photosensitizing mechanism. Free Rad Biol Med 2019;141:103–114. doi:10.1016/j.freeradbiomed.2019.05.024.
   PubMed Web of Science ®Google Scholar
• Ahumada M, Lissi E, Montagut AM, Valenzuela-Henriquez F, Pacioni NL, Alarcon EI. Association models for binding of molecules to nanostructures. Analyst 2017;142(12):2067–2089. doi:10.1039/c7an00288b.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Badimon L, Caballero J, Padro T, Vilahur G, Alarcon M, Perez P, Palomo I. Protective mechanisms of adenosine 5ʹ-monophosphate in platelet activation and thrombus formation. Thromb Haemost 2014;111(3):491–507. doi:10.1160/TH13-05-0386.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005;45(8):1280–1286. doi:10.1016/j.jacc.2004.12.071.
   PubMed Web of Science ®Google Scholar
• Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012;4(4):90–102. doi:10.4330/wjc.v4.i4.90.
   PubMedGoogle Scholar
• Lutz M, Fuentes E, Avila F, Alarcon M, Palomo I. Roles of phenolic compounds in the reduction of risk factors of cardiovascular diseases. Molecules 2019;24. doi:10.3390/molecules24020366.
   PubMed Web of Science ®Google Scholar
• Gawlowski T, Stratmann B, Ruetter R, Buenting CE, Menart B, Weiss J, Vlassara H, Koschinsky T, Tschoepe D. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009;48(8):475–481. doi:10.1007/s00394-009-0038-6.
   PubMed Web of Science ®Google Scholar
• Soaita I, Yin W, Rubenstein DA. Glycated albumin modifies platelet adhesion and aggregation responses. Platelets 2017;28(7):682–690. doi:10.1080/09537104.2016.1260703.
   PubMed Web of Science ®Google Scholar
• Rubenstein DA, Yin W. Glycated albumin modulates platelet susceptibility to flow induced activation and aggregation. Platelets 2009;20(3):206–215. doi:10.1080/09537100902795492.
   PubMed Web of Science ®Google Scholar
• Sadowska-Bartosz I, Galiniak S, Bartosz G. Kinetics of glycoxidation of bovine serum albumin by methylglyoxal and glyoxal and its prevention by various compounds. Molecules 2014;19(4):4880–4896. doi:10.3390/molecules19044880.
   PubMed Web of Science ®Google Scholar
• Tupe RS, Bangar N, Diwan A, Changale D, Choudhary S, Chaware S. Comparative study of different glycating agents on human plasma and vascular cells. Mol Biol Rep 2020;47(1):521–531. doi:10.1007/s11033-019-05158-y.
   PubMed Web of Science ®Google Scholar
• Bauer M, Baumann J, Trommer WE. ATP binding to bovine serum albumin. FEBS Lett 1992;313(3):288–290. doi:10.1016/0014-5793(92)81211-4.
   PubMed Web of Science ®Google Scholar
• Takeda S, Miyauchi S, Nakayama H, Adenosine KN. 5ʹ-triphosphate binding to bovine serum albumin. Biophys Chem 1997;69(2–3):175–183. doi:10.1016/s0301-4622(97)00084-7.
   PubMed Web of Science ®Google Scholar
• Awasthi S, Murugan NA, Saraswathi NT. Advanced glycation end products modulate structure and drug binding properties of albumin. Mol Pharm 2015;12(9):3312–3322. doi:10.1021/acs.molpharmaceut.5b00318.
   PubMed Web of Science ®Google Scholar
• Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994;269(51):32299–32305.
   PubMed Web of Science ®Google Scholar
• Otahbachi M, Simoni J, Simoni G, Moeller JF, Cevik C, Meyerrose GE, Roongsritong C. Gender differences in platelet aggregation in healthy individuals. J Thromb Thrombolysis 2010;30(2):184–191. doi:10.1007/s11239-009-0436-x.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Rojas A, Palomo I. Role of multiligand/RAGE axis in platelet activation. Thromb Res 2014;133(3):308–314. doi:10.1016/j.thromres.2013.11.007.
   PubMed Web of Science ®Google Scholar
• Leoncini G, Maresca M, Buzzi E. Inhibition of the glycolytic pathway by methylglyoxal in human platelets. Cell Biochem Funct 1989;7(1):65–70. doi:10.1002/cbf.290070111.
   PubMed Web of Science ®Google Scholar
• Prestes AS, Dos Santos MM, Ecker A, Zanini D, Schetinger MR, Rosemberg DB, da Rocha JB, Barbosa NV. Evaluation of methylglyoxal toxicity in human erythrocytes, leukocytes and platelets. Toxicol Mech Methods 2017;27(4):307–317. doi:10.1080/15376516.2017.1285971.
   PubMed Web of Science ®Google Scholar
• Blache D, Bourdon E, Salloignon P, Lucchi G, Ducoroy P, Petit JM, Verges B, Lagrost L. Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes. Diabetes 2015;64(3):960–972. doi:10.2337/db14-0879.
   PubMed Web of Science ®Google Scholar
• Davies SS, Brantley EJ, Voziyan PA, Amarnath V, Zagol-Ikapitte I, Boutaud O, Hudson BG, Oates JA, Roberts LJ 2nd. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity. Biochemistry 2006;45:15756–15767. doi:10.1021/bi061860g.
   PubMed Web of Science ®Google Scholar